Can a common supplement shrink fatty liver in a rare diabetes?
NCT ID NCT07748130
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial tests whether taking coenzyme Q10 (CoQ10) for 12 weeks can reduce fat buildup in the liver of people with mitochondrial diabetes, a rare form of diabetes caused by mitochondrial dysfunction. Participants with the m.3243A>G mutation will take 300 mg of CoQ10 daily, and liver fat will be measured using a non-invasive ultrasound technique. The study also compares baseline characteristics among mitochondrial diabetes patients, type 1 diabetes patients, and healthy controls to better understand the link between mitochondrial defects and liver fat.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Coenzyme Q10 (CoQ10) supplement
- What this could lead to
- If CoQ10 reduces liver fat in mitochondrial diabetes, it could become a treatment for this rare condition and possibly for other fatty liver diseases.
- What could go wrong
- This is a small early-stage study with only 30 participants, so results may not apply broadly. CoQ10 may not significantly change liver fat, and the trial does not yet measure long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
1\. Mitochondrial Diabetes Group Inclusion Criteria: 1. Confirmed as a carrier of the mitochondrial DNA m.3243A\>G mutation through genetic testing; 2. Meeting the diagnostic criteria for diabetes (WHO 1999 diagnostic criteria); 3. Aged between 18 and 70 years; 4. Willing to participate and having signed the informed consent form. Exclusion Criteria: 1. Type 1 or type 2 diabetes (not caused by mitochondrial gene mutations); 2. Comorbid with viral hepatitis, drug-induced hepatitis, alcoholic liver disease, Wilson's disease, or other specific diseases that can lead to fatty liver; 3. Severe cardiac, pulmonary, or renal insufficiency; 4. Pregnant or lactating women; 5. Having used coenzyme Q10 or other mitochondrial-targeted drugs within the past 3 months; 6. Having contraindications to MRI examination; 7. Having experienced infection, surgery, or major trauma within the past 4 weeks. Withdrawal/Dropout Criteria: 1. The subject withdraws informed consent; 2. The occurrence of serious adverse events; 3. Loss to follow-up; 4. Medication adherence that continued participation in \< 80%; 5. The researcher believes the study is not in the best interest of the subject. 2. Type 1 Diabetes Control Group Inclusion Criteria: 1. Meeting the diagnostic criteria for type 1 diabetes, with positive islet autoantibodies (GAD, IA-2, ICA, etc.); 2. Aged between 18 and 70 years; 3. Willing to participate and having signed the informed consent form. Exclusion Criteria: Same as the exclusion criteria (1) to (7) for the mitochondrial diabetes group. 3. Healthy Adult Control Group Inclusion Criteria: 1. No history of diabetes, with fasting blood glucose \< 5.6 mmol/L and HbA1c \< 5.7%; 2. Aged between 18 and 70 years; 3. Willing to participate and having signed the informed consent form. Exclusion Criteria: Same as the exclusion criteria (1) to (7) for the mitochondrial diabetes group.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mitochondrial diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The 95th hospital of Putian
Putian, Fujian, 351100, China